Syri Limited, T/A SyriMed is recalling batches of product as a precautionary measure due to crystallisation observed over time in the oral solution.
Similar Posts
Safety Public Assessment Reports
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
MHRA Safety Roundup: June 2025
Summary of the latest safety advice for medicines and medical device users
Device specific vigilance guidance: Artificial Heart Valves
Guidance for manufacturers of artificial heart valves. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Field Safety Notices: 27 to 31 October 2025
List of Field Safety Notices from 27 to 31 October 2025.
MHRA begins recruitment for new digital roles at Leeds hub to drive innovation and smarter regulation
New jobs to strengthen innovation, safety and smarter regulation across the UK health and life sciences sector.
Clinical trials for medicines: notifiable trials
Guidance on categorising certain clinical trials as ‘notifiable’.